Literature DB >> 7165167

Circulating carrier erythrocytes: slow-release vehicle for an antileukemic drug, cytosine arabinoside.

J R DeLoach, C Barton.   

Abstract

The human anti-cancer drug Cytosine arabinoside (ana-C) was encapsulated in canine erythrocytes. When these autologous carrier cells were injected into dogs, the drug was slowly released into plasma. Erythrocyte encapsulation increased the plasma half-life of ara-C in dogs about 50-fold over that of the injected free drug. The whole blood half-life of encapsulated drug was 4.6 days and the elimination constant was 0.150 day-1. Erythrocyte encapsulation holds promise as a drug-delivering technique for treatment of some human and animal diseases, particularly with drugs that are highly toxic or have normally short biological half-life. It also could be used to sustain given concentrations of drugs.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7165167

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  3 in total

1.  Conversion of encapsulated 5-fluoro-2'-deoxyuridine 5'-monophosphate to the antineoplastic drug 5-fluoro-2'-deoxyuridine in human erythrocytes.

Authors:  A De Flora; E Zocchi; L Guida; C Polvani; U Benatti
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

Review 2.  Carrier erythrocytes. Clinical pharmacokinetic considerations.

Authors:  M Tonetti; A De Flora
Journal:  Clin Pharmacokinet       Date:  1993-11       Impact factor: 6.447

3.  Plasma and cerebrospinal fluid pharmacokinetics of cytosine arabinoside in dogs.

Authors:  J C Scott-Moncrieff; T C Chan; M L Samuels; J R Cook; G L Coppoc; D B DeNicola; R C Richardson
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.